Yondelis New Zealand - English - Medsafe (Medicines Safety Authority)

yondelis

specialised therapeutics limited - trabectedin 0.25mg - powder for infusion - 0.25 mg - active: trabectedin 0.25mg excipient: monobasic potassium phosphate phosphoric acid potassium hydroxide sucrose - yondelis is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.